Home » Market News » DirectorsTalk Highlights » 4D to present Phase Ib results of Thetanix in paediatric Crohn’s disease at ESPGHAN meeting
4d Pharma Plc

4D to present Phase Ib results of Thetanix in paediatric Crohn’s disease at ESPGHAN meeting

4D pharma plc today announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn’s disease will be presented by the Lead Investigator, Richard Hansen, Consultant Paediatric Gastroenterologist, Royal Hospital for Children, Glasgow will also give an oral presentation on this data at the 52nd Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) in Glasgow, UK, on 7 June 2019.

 

4D Pharma plc (LON:DDDD) is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.